128 related articles for article (PubMed ID: 20109402)
1. [Melanomas and basal cell carcinomas in a patient with Parkinson disease].
Hiraldo A; Gómez-Moyano E; Martínez S; Sanz A
Actas Dermosifiliogr; 2010; 101(1):95-6. PubMed ID: 20109402
[No Abstract] [Full Text] [Related]
2. [Parkinson disease].
Moore AP; Clarke CE
Praxis (Bern 1994); 2001 Jun; 90(23):1041-6. PubMed ID: 11447724
[No Abstract] [Full Text] [Related]
3. Medical hazards of the internet: gambling in Parkinson's disease.
Larner AJ
Mov Disord; 2006 Oct; 21(10):1789. PubMed ID: 16941457
[No Abstract] [Full Text] [Related]
4. Parkinson's disease.
Clarke C; Moore AP
Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738
[No Abstract] [Full Text] [Related]
5. Parkinson's disease.
Clarke C; Moore A
Clin Evid; 2002 Dec; (8):1370-85. PubMed ID: 12603943
[No Abstract] [Full Text] [Related]
6. Parkinson's disease.
Barboi AC; Goetz CG
Clin Neuropharmacol; 1999; 22(4):184-91. PubMed ID: 10442246
[No Abstract] [Full Text] [Related]
7. [Parkinson disease therapy: how great is the progress? Possibilities, limitations and future prospects?].
Schulz-Hanke I
Dtsch Med Wochenschr; 2003 Dec; 128(51-52):2689-90. PubMed ID: 14725284
[No Abstract] [Full Text] [Related]
8. [Pergolide: a useful agonist for the treatment of Parkinson disease].
Bonnet AM; Houeto JL
Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
[TBL] [Abstract][Full Text] [Related]
9. Peripheral edema and dopamine agonists in Parkinson disease.
Tan EK
Arch Neurol; 2007 Oct; 64(10):1546-7; author reply 1547. PubMed ID: 17923645
[No Abstract] [Full Text] [Related]
10. Future therapies for Parkinson's disease.
Hauser RA; Lyons KE
Neurol Clin; 2004 Oct; 22(3 Suppl):S149-66. PubMed ID: 15501363
[No Abstract] [Full Text] [Related]
11. [Parkinson disease. Directed use of modern therapy].
Möller JC; Wächter T; Oertel WH
MMW Fortschr Med; 2001 May; 143 Suppl 2():45-50. PubMed ID: 11434257
[TBL] [Abstract][Full Text] [Related]
12. When and how should treatment be started in Parkinson disease?
Lang AE
Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
[TBL] [Abstract][Full Text] [Related]
13. Agonists versus levodopa in PD: the thrilla of whitha.
Montgomery EB
Neurology; 2003 Nov; 61(10):1462; author reply 1462-3. PubMed ID: 14638991
[No Abstract] [Full Text] [Related]
14. Use of apomorphine in Parkinson's disease.
Stocchi F
Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of later phases of Parkinson disease].
Tison F
Rev Neurol (Paris); 2008 Apr; 164 Spec No 2():F85-8. PubMed ID: 18680823
[No Abstract] [Full Text] [Related]
16. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
Kondo T
J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
[TBL] [Abstract][Full Text] [Related]
17. [Medicinal treatment of idiopathic Parkinson's disease].
Klockgether T
Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
[TBL] [Abstract][Full Text] [Related]
18. Effective strategies in the management of Parkinson's disease.
Wills AJ
Hosp Med; 1998 Apr; 59(4):287-90. PubMed ID: 9722367
[TBL] [Abstract][Full Text] [Related]
19. Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa.
Marek K; Jennings D; Seibyl J
Neurology; 2003 Sep; 61(6 Suppl 3):S43-8. PubMed ID: 14504379
[No Abstract] [Full Text] [Related]
20. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
